Cargando…

Effect of different chemotherapy schemes on early-stage breast cancer patients with Low HER-2 expression

OBJECTIVE: To explore the effect of different chemotherapy schemes on the prognosis, immune function and adverse reactions of breast cancer patients with low HER-2 expression after surgery. METHODS: A retrospective analysis was carried out on the clinical data of 60 breast cancer patients with low H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Yurui, Chao, Lin, Wang, Jianyu, Sun, Yonghong, Li, Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Professional Medical Publications 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480763/ https://www.ncbi.nlm.nih.gov/pubmed/37680804 http://dx.doi.org/10.12669/pjms.39.5.7446

Ejemplares similares

miRNA-148a regulates the expression of the estrogen receptor through DNMT1-mediated DNA methylation in breast cancer cells
por: Xu, Yurui, et al.
Publicado: (2017)

Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly
por: Sun, J, et al.
Publicado: (2017)

Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer
por: Yang, Tao, et al.
Publicado: (2022)

Effect of PREDICT on chemotherapy/trastuzumab recommendations in HER2-positive patients with early-stage breast cancer
por: DOWN, SUE K., et al.
Publicado: (2014)

Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
por: Ilie, Silvia Mihaela, et al.
Publicado: (2023)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
por: Zhou, Shuling, et al.
Publicado: (2022)

Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience
por: Xu, Hangcheng, et al.
Publicado: (2022)

Clinicopathological characteristics and prognosis of early-stage HER2 low-expression breast cancer: A single-center retrospective study
por: Liu, Chang-Gen, et al.
Publicado: (2023)

Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
por: Hong, Joohyun, et al.
Publicado: (2022)

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2022)

Treatment of early-stage HER2+ breast cancer—an evolving field
por: Ferreira, Arlindo R, et al.
Publicado: (2015)

Neratinib for the Treatment of Early-Stage HER2-Positive Breast Cancer
por: Miles, Jennifer, et al.
Publicado: (2018)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer
por: Cherifi, François, et al.
Publicado: (2022)

Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
por: Chen, Zhaoxu, et al.
Publicado: (2023)

Analysis of clinicopathological characteristics and prognostic factors of early‐stage human epidermal growth factor receptor 2 (HER2)‐low breast cancer: Compared with HER2‐0 breast cancer
por: Wu, Qian, et al.
Publicado: (2023)

Role of androgen receptor expression in early stage ER+/PgR−/HER2– breast cancer
por: Tagliaferri, Barbara, et al.
Publicado: (2020)

Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study
por: Tang, Lingfeng, et al.
Publicado: (2022)

Oncotype Dx Score, HER2 Low Expression, and Clinical Outcomes in Early-Stage Breast Cancer: A National Cancer Database Analysis
por: Roy, Arya Mariam, et al.
Publicado: (2023)

Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy
por: Ma, Youzhao, et al.
Publicado: (2023)

Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer
por: Mutai, Raz, et al.
Publicado: (2021)

Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer
por: Dackus, Gwen M. H. E., et al.
Publicado: (2020)

Exploring Real-World HER2-Low Data in Early-Stage Triple-Negative Breast Cancer: Insights and Implications
por: da Silva, Jesse Lopes, et al.
Publicado: (2023)

HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series
por: Rothschild, Harriet T., et al.
Publicado: (2023)

Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer
por: Sanomachi, Tomomi, et al.
Publicado: (2023)

Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
por: Yan, Hui, et al.
Publicado: (2020)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
por: Cai, Mengyuan, et al.
Publicado: (2023)

Analysis of Genomic Alterations Associated with Recurrence in Early Stage HER2-Positive Breast Cancer
por: Kim, Yong-Seok, et al.
Publicado: (2022)

Predicting Chemotherapy Benefit across Different Races in Early-Stage Breast Cancer Patients Using the Oncotype DX Score
por: Shaw, Vikram R., et al.
Publicado: (2023)

Benefits of Adjuvant Chemotherapy Differ by Menopausal Status in Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Recurrence Score
por: Jacobson, Anne
Publicado: (2022)

EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
por: Leichsenring, Jonas, et al.
Publicado: (2022)

Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer
por: Alves, Fátima R, et al.
Publicado: (2022)

Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
por: Kourie, Hampig Raphael, et al.
Publicado: (2017)

The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer
por: Pop, Lucian, et al.
Publicado: (2019)

PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
por: Agostinetto, Elisa, et al.
Publicado: (2022)

Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer
por: Terán, Santiago, et al.
Publicado: (2023)

Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib
por: Sharaf, Baha’, et al.
Publicado: (2023)

The role of radiotherapy in HER2+ early-stage breast cancer patients after breast-conserving surgery
por: Yang, Huanzuo, et al.
Publicado: (2023)

Chemotherapy for early-stage breast cancer: a brief history
por: Verrill, M
Publicado: (2009)

Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
por: Agostinetto, Elisa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_29i31djqqt2e11pm354r1d38s3